Servier appoints Yposkesi for lentiviral vector GMP-manufacturing in CAR-T cell development technology

Service agreement gives Servier access to Yposkesi’s robust production capacity

Servier, an international independent pharmaceutical company, and Yposkesi, a leading CDMO for gene therapy viral vector manufacturing, today announce that they have signed a manufacturing service agreement. Servier selected Yposkesi to develop and GMP manufacture lentiviral vectors to support allogenic CAR-T cell technology development.

Read more